2 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Speech Disorders: new trials by email Literature Review of Speech Disorders trials Research Report on Speech Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dopamine and Sensorimotor Function in Stuttering Aripiprazole 10 MG, Placebo - Stuttering, Adult | Phase 1 | Recruiting | University of California, San Francisco | 25 | 2025-09-30 | 2026-08-19 |
| A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101 - Frontotemporal Dementia, FTD | Phase 1 / Phase 2 | Recruiting | AviadoBio Ltd | 18 | 2023-08-30 | 2026-08-13 |
Aphasia, Primary Progressive (1) · Dementia (1) · Frontotemporal Dementia (1) · Stuttering (1)
Communication Disorders (2) · Language Disorders (2) · Nervous System Diseases (2) · Neurobehavioral Manifestations (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Aphasia (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Frontotemporal Lobar Degeneration (1) · Mental Disorders (1) · Metabolic Diseases (1) · Neurocognitive Disorders (1)
Aripiprazole (1)
AviadoBio Ltd (1) · University of California, San Francisco (1)
United States (2) · Belgium (1) · Canada (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Sweden (1) · United Kingdom (1)
John Houde, PhD (1) · Ludo Max, PhD (1) · Srikantan Nagarajan, PhD (1)
2023 (1), R21DC021557 (1)